Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

NCT00184366 · clinicaltrials.gov ↗
TERMINATED
Status
96
Enrollment
OTHER
Sponsor class

Stopped efalizumab was withdrawn from market; full 2 years follow-up only 14 patients

Conditions

Interventions

Sponsor

Norwegian University of Science and Technology